Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
40
MREO Quote, Financials, Valuation and Earnings
Last price:
$3.38
Seasonality move
:
18.25%
Day range:
$3.22 - $3.39
52-week range:
$2.03 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.25x
Volume:
524.1K
Avg. volume:
996K
1-year change:
59.15%
Market cap:
$525.9M
Revenue:
$10M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.02 | 1109.31% | -69.36% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$7M | -$0.78 | 16.38% | -23.21% | $33.36 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
$1.1M | -$1.77 | -- | -59.89% | -- |
|
NCNA
NuCana PLC
|
-- | -$3.95 | -- | -98.11% | $64.50 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$3.39 | -- | $525.9M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$14.54 | $33.36 | $1B | -- | $0.00 | 0% | 20.30x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$3.82 | -- | $2.2M | -- | $0.00 | 0% | 3.44x |
|
DBVT
DBV Technologies SA
|
$3.30 | -- | $67.6M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$1.21 | $64.50 | $4.7M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.64 | -- | $5.2M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -0.254 | -- | -- |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.257 | -- | 16.82x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -0.249 | -- | -- |
|
NCNA
NuCana PLC
|
-- | 1.608 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$63.5M | -27.99% | -29.19% | -2026.05% | -$40.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
NCNA
NuCana PLC
|
-- | -$6.6M | -- | -- | -- | -$6.4M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -1898.43%. Mereo BioPharma Group PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BCYCBicycle Therapeutics PLC-- -$0.74 $831M -
What do Analysts Say About MREO or BCYC?
Mereo BioPharma Group PLC has a consensus price target of --, signalling upside risk potential of 111.29%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.36 which suggests that it could grow by 129.46%. Given that Bicycle Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC0 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is MREO or BCYC More Risky?
Mereo BioPharma Group PLC has a beta of 0.935, which suggesting that the stock is 6.519% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.196%.
-
Which is a Better Dividend Stock MREO or BCYC?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BCYC?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $2.7M. Mereo BioPharma Group PLC's net income of -$15M is higher than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 20.30x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M BCYCBicycle Therapeutics PLC20.30x -- $2.7M -$50.8M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of --, signalling upside risk potential of 111.29%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 109.82%. Given that Mereo BioPharma Group PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC0 0 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.935, which suggesting that the stock is 6.519% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 3.44x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M BDRXBiodexa Pharmaceuticals PLC3.44x -- -- --
-
Which has Higher Returns MREO or DBVT?
DBV Technologies SA has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About MREO or DBVT?
Mereo BioPharma Group PLC has a consensus price target of --, signalling upside risk potential of 111.29%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 568.05%. Given that DBV Technologies SA has higher upside potential than Mereo BioPharma Group PLC, analysts believe DBV Technologies SA is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC0 0 0 DBVTDBV Technologies SA0 0 0 -
Is MREO or DBVT More Risky?
Mereo BioPharma Group PLC has a beta of 0.935, which suggesting that the stock is 6.519% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.
-
Which is a Better Dividend Stock MREO or DBVT?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or DBVT?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns MREO or NCNA?
NuCana PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- NCNANuCana PLC-- -$2.28 -- -
What do Analysts Say About MREO or NCNA?
Mereo BioPharma Group PLC has a consensus price target of --, signalling upside risk potential of 111.29%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 5230.58%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC0 0 0 NCNANuCana PLC1 2 0 -
Is MREO or NCNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.935, which suggesting that the stock is 6.519% less volatile than S&P 500. In comparison NuCana PLC has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.593%.
-
Which is a Better Dividend Stock MREO or NCNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or NCNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is lower than NuCana PLC's net income of -$5.9M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M NCNANuCana PLC-- -- -- -$5.9M
-
Which has Higher Returns MREO or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About MREO or TCBP?
Mereo BioPharma Group PLC has a consensus price target of --, signalling upside risk potential of 111.29%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 371.7%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC0 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is MREO or TCBP More Risky?
Mereo BioPharma Group PLC has a beta of 0.935, which suggesting that the stock is 6.519% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MREO or TCBP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or TCBP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is down 8.7% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is up 9.77% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is up 7.96% over the past day.
